Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Clin Cancer Res. 2019 Feb 18;25(11):3229–3238. doi: 10.1158/1078-0432.CCR-18-2675

Figure 3.

Figure 3.

Percentage of huCD45+ cells in peripheral blood over time (A), and event-free survival curves (B) for ALL-19 engrafted NOD/SCID mice treated with alisertib at 10.4 mg/kg twice daily for 7 days (Schedule A, red), or twice daily for 5 days repeated for 3 weeks (Schedule B, blue) in relation to vehicle-treated controls (dotted line).